RXi Pharmaceuticals Corp.

RXi Pharmaceuticals Corp. is a biotechnology company focused on discovering, developing and commercializing innovative therapies based on its proprietary, next-generation RNAi platform. Therapeutics that use RNA interference, or "RNAi," have great promise because of their ability to "silence," or down-regulate, the expression of a specific gene that may be overexpressed in a disease condition. RXi's first RNAi product candidate, RXI-109, is currently in clinical trials. It targets connective tissue growth factor, a key regulatory of fibrosis and scar formation, and is initially being developed to reduce or inhibit scar formation in the skin following surgery.

Expert Comments:

Keith Markey, Griffin Securities (4/1/15)
"Investors have overlooked RXi Pharmaceuticals Corp. shares as evidenced by the discrepancy between the company's $15M market capitalization and the status of its drugs in clinical development and the multibillion dollar sales potential of the research and development pipeline. Accordingly, we are affirming our Buy recommendation with a price target of $4.25."

Reni Benjamin, H.C. Wainwright & Co. (3/31/15)
"We are reiterating our Buy rating of RXi Pharmaceuticals Corp. . .the company has three ongoing Phase 2 clinical studies utilizing optimized RNA interference (RNAi) therapeutics, including two in hypertrophic and one in keloid scarring. . .with a proprietary RNAi platform focused on dermal and ophthalmologic applications, a topical immunomodulatory asset with known efficacy in cosmetic indications, and a pro forma cash position of $6.8M, we believe RXi represents an undervalued player with upside for the long-term investor. .yesterday, RXi reported a Q4/14 net loss of ($2.8M), or ($0.13) per share, comparable to our estimate of ($2.8M), or ($0.14) per share."

Reni Benjamin, H.C. Wainwright & Co. (12/22/14)
"We are reiterating our Buy rating of RXi Pharmaceuticals Corp. . .the company announced a global licensing agreement with Hapten Pharmaceuticals LLC for rights to Samcyprone, a standardized formulation of the topical immunosensitizer, diphenylcyclopropenone. In our opinion, the agreement diversifies RXi's pipeline with a non-RNA interference product that has demonstrated efficacy in several investigator-sponsored trials for the treatment of viral warts, patchy hair loss (alopecia areata) and cutaneous metastases."

Reni Benjamin, H.C. Wainwright & Co. (11/18/14)
"We are reiterating our Buy rating of RXi Pharmaceuticals Corp. and a target price of $9. . .with a strong proprietary RNAi platform focused on dermal and ophthalmologic applications, a derisked lead asset with the potential to enter multiple therapeutic areas and a cash position of $10.1M, we believe the company represents an undervalued player with significant upside for the long-term investor."

Edward White, Laidlaw & Company (10/8/14)
"The Phase 2a photos of hypertrophic scar patients treated with RXi Pharmaceuticals Corp.'s RXI-109 following scar revision surgery presented yesterday showed significant improvement compared to placebo at three months, in our opinion. . .we are maintaining our Buy rating and price target. Our price target for the company is $8."

"RXi Pharmaceuticals Corp. has done extensive clinical trials and/or extensive research both at preclinical and clinical levels with its lead molecule, which targets a growth factor called connective tissue growth factor that plays a central role in the formation of scars. . .the company is developing products that are relatively easy to administer to the specific areas that need to be treated. By that I mean dermatological indications, which are very easily accessible, and also the eye, for ophthalmic diseases. That's RXi's way of mitigating some of the risk from the delivery point of view. Its molecules also are designed specifically to facilitate the uptake of their therapeutic payload, so that's not an issue that has to be considered separately. . .the [Phase 2] trial was designed to optimize the treatment regimen, and the one-month data did just that—the first interim analysis showed that a delayed administration of RXI-109 yielded better results than injection near the time of the surgery. . . read more >

More Expert Comments

Experts Commenting on This Company

Reni Benjamin, Managing Director – H.C. Wainwright & Co.
Keith Markey, Scientific Director – Griffin Securities
Edward White – FBR Capital Markets

The information provided above is from analysts, newsletters and other contributors. Please contact the company and visit its website before making an investment decision.
Investing Highlights
Multiple development opportunities within the Company's Dermatology and Ophthalmology franchises
Leader in the development of advanced RNAi-based therapeutics
Broad and robust intellectual property portfolio
catalyst Calendar
RXI-109-1301: study to be completed in 2015
RXi Pharmaceuticals Corp. Content